Tokyo Tape
Sign in
← OncoTherapy Science

Half-year report · Q2

4564.TEDINET S100UOSE
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥225m2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥531m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥545m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥545m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥546m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥546m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.5bnat 2024-09-30Cons.Assets
Total assets¥867mat 2024-03-31Cons.Assets
Total assets¥1.2bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥548mat 2024-09-30Cons.Liabilities
Total liabilities¥514mat 2024-03-31Cons.Liabilities
Net assets / equity¥1.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥354mat 2024-03-31Cons.Net assets
Net assets / equity¥935mat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥528mat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥528mat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥579m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥33m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.1bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥671m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-2.182024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-6.052023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio59.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥178m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥222m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥222m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥94m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥135,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥259m
—segment totalrevenue2024-04-01 → 2024-09-30¥225m
—segment totalrevenue external2024-04-01 → 2024-09-30¥225m
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥135,000
—segment totalsegment profit2024-04-01 → 2024-09-30−¥353m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 411
ItemContextValueUnit
Other caPrior1YearInstant104570000JPY
Other caCurrentQuarterInstant139173000JPY
Current assetsPrior1YearInstant817769000JPY
Current assetsCurrentQuarterInstant1498587000JPY
Investments and other assetsPrior1YearInstant49505000JPY
Investments and other assetsCurrentQuarterInstant49505000JPY
Noncurrent assetsPrior1YearInstant49505000JPY
Noncurrent assetsCurrentQuarterInstant49505000JPY
AssetsPrior1YearInstant867275000JPY
AssetsCurrentQuarterInstant1548092000JPY
Accounts payable otherPrior1YearInstant139436000JPY
Accounts payable otherCurrentQuarterInstant203447000JPY
Contract liabilitiesPrior1YearInstant197432000JPY
Contract liabilitiesCurrentQuarterInstant128779000JPY
Income taxes payablePrior1YearInstant2425000JPY
Income taxes payableCurrentQuarterInstant74210000JPY
Other clPrior1YearInstant20299000JPY
Other clCurrentQuarterInstant15157000JPY
Current liabilitiesPrior1YearInstant359593000JPY
Current liabilitiesCurrentQuarterInstant421595000JPY
Long term accounts payable otherPrior1YearInstant106849000JPY
Long term accounts payable otherCurrentQuarterInstant78922000JPY
Asset retirement obligations nclPrior1YearInstant47165000JPY
Asset retirement obligations nclCurrentQuarterInstant47225000JPY
Noncurrent liabilitiesPrior1YearInstant154015000JPY
Noncurrent liabilitiesCurrentQuarterInstant126148000JPY
LiabilitiesPrior1YearInstant513608000JPY
LiabilitiesCurrentQuarterInstant547743000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant647141000JPY
Capital surplusPrior1YearInstant26322132000JPY
Capital surplusCurrentQuarterInstant26919273000JPY
Retained earningsPrior1YearInstant-26092962000JPY
Retained earningsCurrentQuarterInstant-26638661000JPY
Treasury stockPrior1YearInstant-2000JPY
Treasury stockCurrentQuarterInstant-3000JPY
Shareholders equityPrior1YearInstant279166000JPY
Shareholders equityCurrentQuarterInstant927748000JPY
Subscription rights to sharesPrior1YearInstant74500000JPY
Subscription rights to sharesCurrentQuarterInstant72600000JPY
Net assetsPrior1YearInstant353666000JPY
Net assetsCurrentQuarterInstant1000348000JPY
Liabilities and net assetsPrior1YearInstant867275000JPY
Liabilities and net assetsCurrentQuarterInstant1548092000JPY
Business revenuePrior1YTDDuration356452000JPY
Business revenueCurrentYTDDuration225083000JPY
Cost of salesPrior1YTDDuration444847000JPY
Cost of salesCurrentYTDDuration289539000JPY
Research and development expenses sgaPrior1YTDDuration405761000JPY
Research and development expenses sgaCurrentYTDDuration262376000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass